# Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates

> **NCT03507348** · NA · TERMINATED · sponsor: **University Hospital, Grenoble** · enrollment: 8 (actual)

## Conditions studied

- End-stage Renal Disease
- Kidney Transplantation
- Hla-incompatible Kidney Transplant Candidates

## Interventions

- **DRUG:** visits of tocilizumab injection (every 4 weeks, up to 5 visits)
- **DRUG:** Rituximab 375 mg/m2 at Day-30
- **DRUG:** Rituximab 375 mg/m2 at Day-15 (only for donors living)
- **OTHER:** Transplant Day-0

## Key facts

- **NCT ID:** NCT03507348
- **Lead sponsor:** University Hospital, Grenoble
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-07-01
- **Primary completion:** 2019-11-21
- **Final completion:** 2019-11-21
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** investigateur decision
- **Last updated:** 2020-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03507348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03507348, "Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03507348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*